Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial
Conditions
Interventions
Efavirenz-Tenofovir-Emtricitabine
Zidovudine-Lamivudine-Lopinavir/Ritonavir
Locations
2
Côte d’Ivoire
Programme PAC-CI, site ANRS
Abidjan, Côte d’Ivoire
Center for Infectious Desease Reserach in Zambia
Lusaka, Zambia
Start Date
January 1, 2010
Primary Completion Date
January 1, 2013
Completion Date
June 1, 2013
Last Updated
February 15, 2012
NCT04929028
NCT06768060
NCT07462065
NCT04142047
NCT06694805
NCT06273683
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions